Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
- Legacy Emanuel Children's Hospital — Portland, Oregon
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Hood River Memorial Hospital — Hood River, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Oregon: - Oncology Associates of Oregon Willamette Valley Cancer Center — Eugene, Oregon
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Sites in Oregon: - Providence Neurological Specialties West — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Oregon: - Oregon Health and Science University ( Site 5425) — Portland, Oregon
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Oregon: - Providence Health & Services — Portland, Oregon
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Oregon: - Oncology Associates of Oregon — Eugene, Oregon
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-H…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in Oregon: - Oncology Associates of Oregon, P.C — Eugene, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Oregon: - Providence Neurological Specialties West — Portland, Oregon
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Oregon: - Williamette Valley Cancer Institute & Research Center — Eugene, Oregon
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …
Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Oregon: - Doernbecher Children's Hospital — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
Sponsor: AstraZeneca
NCT ID: NCT06564038
Sites in Oregon: - Research Site — Portland, Oregon
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumu…
Sponsor: Indapta Therapeutics, INC.
NCT ID: NCT06119685
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
Phase 1, Phase 2 Recruiting Academic/Other
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B …
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06249191
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1, Phase 2 Recruiting Academic/Other
This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06357676
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each particip…
Sponsor: Eli Lilly and Company
NCT ID: NCT07226843
Sites in Oregon: - Oregon Health & Science University (OHSU) — Portland, Oregon
Phase 1 Recruiting Industry
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Sponsor: Schrödinger, Inc.
NCT ID: NCT05544019
Sites in Oregon: - Oregon Health and Science University - Knight Cancer Institute — Portland, Oregon
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
Recruiting Network
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Newberg Medical Center — Newberg, Oregon